Return to Listing

9 result(s) for Breast Cancer

PI Name Protocol # Title
Kathleen Kemmer IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Kathleen Kemmer IRB00011351 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Jacqueline Vuky STUDY00015006 A Phase III, Double-Blind Placebo-Controlled, Randomized Study of Taselisib plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer who have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy.
Arpana Naik STUDY00015164 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Kathleen Kemmer STUDY00015176 A Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)
Kathleen Kemmer STUDY00015366 ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Jacqueline Vuky STUDY00015690 CLEE011X2106: A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer
Lissi Hansen STUDY00015713 Nurse Navigation: The experience of older adult female breast cancer patients.
Raymond Bergan STUDY00016113 Molecular Mechanisms of Tumor Evolution and Resistance to Therapy

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080